Home/Healthcare & Aging Society/Sysmex Corporation

Sysmex Corporation

6869.TMEDIUM

Core — IVD / Lab Equipment · Weight: 8%· Data as of 2026-05-04

Investment Thesis

Global #1 in hematology analyzers (~30% world share, 85% US market via CellaVision alliance, 65,000+ installed analyzers). Business model is an annuity: ~60% revenue is reagents locked in for 5-8 years per analyzer installation, plus 13% service contracts = 73% recurring. EBITDA margin 25.3% and >70% customer retention reflect a structural moat that Mindray (China) and Beckman Coulter cannot replicate in regulated US/EU markets. FY2026 full year results due May 14 2026 are a near-term catalyst.

Risk

1) Q1 FY2026 operating profit down 36.5% YoY — investigate whether structural or seasonal before adding more. 2) Chinese competitors (Mindray, Autobio) winning emerging market share with lower-cost analyzers; if regulatory acceptance expands to US/EU this erodes pricing power. 3) Market cap ¥888B = mid-cap; liquidity risk in Japan small-cap strategy. 4) EPS missed expectations FY2025 by 7.3% — execution tracking required.

Monitoring Trigger

If May 14 FY2026 earnings show full-year OP above ¥80B (+20% vs estimated FY2025), ADD to 10% (confirms reagent model resilience). If Mindray gains FDA 510(k) clearance for XN-equivalent analyzer, reduce to 5% (moat erosion signal). Watch Japan segment growth at each quarterly result.

Key Dates

2026-05-14earningsSysmex FY2026 full-year results — key catalyst. Watch OP trajectory vs Q1 FY2026 decline (-36.5%).

2026-11earningsQ2 FY2027 — validate reagent growth rate and China competitive impact

Update History

2026-05-04exploreNEW

View report →

NEW — Added to Healthcare theme via T-glass gap analysis. Global #1 hematology with reagent annuity moat. LabCorp + Siemens OEM + QIAGEN supply chain confirmed.

status:not in themeadded

Key Metrics

22.5

N/A

Fwd PE

~3.0 (est.)

P/B

N/A

ROE

~20% (est. from EBITDA 25.3%)

Op Margin

N/A

D/E

2.6%

Div Yield

N/A

FCF

¥888B

Mkt Cap

Business Segments

Segment	Revenue	Share	Description
Hematology (blood cell counting/morphology)
Hemostasis (coagulation testing)
Urinalysis
Life Science (cancer diagnostics)

Supply Chain Evidence

Evidence	Customer	Product	Detail
confirmed	LabCorp (US) — primary reference laboratories	XN-Series hematology automation system	Multi-year extended agreement since 2006; LabCorp test volumes up 50% using Sysmex. Most recent extension announced 2019.[source](2019-09-19)
confirmed	Siemens Healthineers (global) — OEM partner	Hemostasis (coagulation) instruments + reagents	25+ year global OEM partnership; both companies distribute joint portfolio under their own brands. Agreement extended 2023.[source](2023-01-01)
confirmed	QIAGEN (Japan market) — alliance partner	Clinical diagnostic products for infectious diseases and oncology	Exclusive strategic alliance for Japan market; Sysmex distributes QIAGEN clinical diagnostic instruments + reagents in molecular diagnostics. Signed Sep 2025.[source](2025-10-01)
confirmed		Hematology analyzers — global competitive set	Top-5 globally per MarketsandMarkets; Sysmex leads in high-complexity hospital and reference lab. Mindray is the key emerging-market threat.[source](2025-01-01)

Sources & References

↗↗↗↗↗↗

Peer Comparison

Company	PE	Fwd PE	ROE	Op Margin	FCF
Nihon Kohden Corporation	20.3	18.9	7.1%	7.97%	N/A
M3, Inc.	19.4	17.9	12.2%	20.9%	N/A
Fukuda Denshi Co., Ltd.	15.87	15.66	8.6%	18.0%	+¥21B
JMDC Inc.	35.85	29.06	7.8%	22.3%	+¥9B
PHC Holdings Corporation	38.5	10.71	0.6%	6.2%	+¥32B
Sysmex Corporation	22.5	N/A	N/A	~20% (est. from EBITDA 25.3%)	N/A
Olympus Corporation	22.98	N/A	N/A	18.9% (adj FY2025)	+¥109B (adj FY2025)